Pfizer, BioNTech seek FDA EUA for Covid-19 vaccine BNT162b2
The companies have already begun rolling submissions across the globe including in Australia, Canada, Europe, Japan and the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Nov 20
The companies have already begun rolling submissions across the globe including in Australia, Canada, Europe, Japan and the…
23 Nov 20
The research collaboration will leverage ARCUS genome editing technology, and initially include three gene targets
20 Nov 20
Novartis will make upfront cash payment of $50m and equity/share subscription, plus performance-based milestones and royalties
20 Nov 20
Baricitinib plus remdesivir is indicated for Covid-19 patients who require supplemental oxygen, invasive mechanical ventilation, or ECMO
19 Nov 20
The primary efficacy analysis in 170 confirmed cases of Covid-19 showed that BNT162b2 is 95% effective in preventing…
19 Nov 20
The EC authorisation is based on clinical data from two Phase 3 trials in a total of more…
18 Nov 20
The FDA breakthrough therapy designation is based on results from a randomised, multicentre, double-blind Phase 2b/3 study HPTN…
17 Nov 20
Moderna intends to seek the US FDA’s Emergency Use Authorisation (EUA) based on the interim data analysis of…
17 Nov 20
Lead and Roche will work together in research activities pertaining selection of a pre-clinical candidate for immune mediated…
16 Nov 20
Xofluza is an advanced antiviral, designed to inhibit the cap-dependent endonuclease protein, which is essential for viral replication